deltatrials
Completed NA NCT00745589

Sevelamer Hydrochloride in Peritoneal Dialysis Patients

Use of Sevelamer Hydrochloride to Control Hyperphosphatemia and Reduce Calcification Burden in the Poor Peritoneal Dialysis Patients

Sponsor: The University of Hong Kong

Conditions Endstage Renal Disease
Interventions sevelamer hydrochloride
Updated 7 times since 2017 Last updated: Jun 17, 2020 Started: Jul 31, 2008 Primary completion: Oct 31, 2014 Completion: Jan 31, 2015

Listed as NCT00745589, this NA trial focuses on Endstage Renal Disease and remains completed. Sponsored by The University of Hong Kong, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jul 2020 — Jan 2021 [monthly]

    Completed NA

  5. Jun 2018 — Jul 2020 [monthly]

    Completed NA

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed NA

  2. Jan 2017 — Feb 2017 [monthly]

    Completed NA

    First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The University of Hong Kong
Data source: The University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Hong Kong, Hong Kong